Cantargia AB ( ($SE:CANTA) ) has shared an update. Cantargia AB has published preclinical data in Cancer Discovery, highlighting the potential of ...

Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical models Anti-IL1RAP ADC targets ...

Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first quarter of ...

said Prof. Thomas Bieber, MD, PhD, MDRA, Professor of Dermatology and Allergy, Davos and Zurich, Switzerland CAN10 is an antibody against IL1RAP designed to potently inhibit the activity of the ...

Clinical findings from nadunolimab studies reflect these preclinical effects of IL1RAP blockade and suggest translatability to clinical benefit. Cantargia (Cantargia AB (publ); Nasdaq Stockholm ...

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, ...

Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical modelsAnti-IL1RAP ADC targets IL1RAP, which is overexpressed in many tumors and their tumor microenvironm ...

Preclinical data shows IL1 family signals mediate systemic immune suppression.Blocking IL1RAP can overcome resistance to immune therapy ...